8-K: Bionomics Limited Enters At-the-Market Offering Agreement with H.C. Wainwright & Co., LLC

Bionomics Limited has entered into an agreement with H.C. Wainwright & Co., LLC for an at-the-market offering of American Depositary Shares (ADS) up to $2 million.

Summary

• Bionomics Limited has established an at-the-market (ATM) offering agreement with H.C. Wainwright & Co., LLC.
• The agreement allows Bionomics to sell American Depositary Shares (ADS) up to a total of $2 million.
• H.C. Wainwright will act as the company's agent for these sales.
• The sales will be made at prevailing market prices.
• The company will pay H.C. Wainwright a commission of 3.0% of the gross proceeds from each sale.
• Bionomics will also reimburse H.C. Wainwright for legal fees up to $50,000.
• The offering is made under a shelf registration statement filed on November 18, 2024.
• The company is not obligated to sell any shares under this agreement.
• The agreement replaces a previous ATM offering with Cantor Fitzgerald & Co. which was terminated.
• The offering will terminate when $2 million of ADSs have been sold or if either party terminates the agreement.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The company is taking steps to secure funding, but there is no guarantee of success. The terms of the agreement are standard, and the company is replacing a previous agreement with this new one.

Positives

• The company has secured a new avenue for raising capital through an at-the-market offering.
• The agreement provides flexibility, allowing the company to sell shares as needed.
• The company has terminated a previous agreement to pursue this new offering.

Negatives

• The company is not obligated to sell any shares, so there is no guarantee of capital being raised.
• The company will incur commission and legal expenses related to the offering.

Risks

• There is no guarantee that the company will sell any shares under the agreement.
• The market price of the ADSs could fluctuate, affecting the amount of capital raised.
• The company is subject to market conditions and may not be able to sell shares at desired prices.

Future Outlook

The company may sell up to $2 million in ADSs through the at-the-market offering, but there is no guarantee of sales or the price at which they will be sold. The offering will terminate upon the sale of $2 million in ADSs or earlier termination by either party.

Industry Context

At-the-market offerings are a common method for companies to raise capital, providing flexibility and access to the market. This agreement allows Bionomics to raise funds as needed without a traditional underwritten offering.

Comparison to Industry Standards

• At-the-market offerings are a common practice for publicly listed companies, particularly in the biotech sector, to raise capital.
• The 3% commission is within the typical range for such agreements.
• The $50,000 cap on legal fees is also a standard provision.
• Comparable companies such as Xometry, Inc. and Amyris, Inc. have used similar ATM offerings to raise capital.
• The size of the offering, $2 million, is relatively small compared to some other ATM offerings, which can range from tens to hundreds of millions of dollars.

Stakeholder Impact

• Shareholders may experience dilution if the company sells a significant number of shares.
• The company will have access to additional capital, which could be used for growth and development.
• The company's financial position may be strengthened by the capital raise.

Next Steps

• The company will begin selling ADSs through H.C. Wainwright & Co., LLC.
• The company will monitor market conditions and sell shares as needed.
• The company will file a prospectus supplement related to the offering.

Key Dates

Keywords

at-the-market offering, ADS, American Depositary Shares, capital raise, H.C. Wainwright, Bionomics Limited, equity offering, sales agreement, securities, placement